Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 8-K (Current Report)
Date of Report: January 22, 2026
Reporting Period: Event-based report for January 22, 2026
The filing reports a significant clinical development event under Item 8.01 (Other Events). The Company announced that its pivotal Phase 3 trial, ROSELLA, evaluating relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the successful completion of the ROSELLA Phase 3 trial's primary endpoint. This represents a significant milestone in the Company's oncology pipeline, specifically for the treatment of platinum-resistant ovarian cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the trial results. No specific financial guidance or forward-looking projections are included in the text of this 8-K.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard implications of clinical trial outcomes. Investors should refer to the attached press release for detailed commentary on the trial results and potential regulatory pathways.
Key Facts for Investor Verification
- Verify the specific statistical significance and hazard ratio for the overall survival endpoint in the attached press release (Exhibit 99.1).
- Confirm the next steps for regulatory submission (e.g., NDA filing timeline) following the Phase 3 success.
- Review the Company's most recent 10-K or 10-Q for current financial health, cash runway, and debt levels, as this 8-K contains no financial data.
- Assess the competitive landscape for platinum-resistant ovarian cancer treatments to gauge the commercial potential of relacorilant.